ESR1 and neoplasm: However, when corrected for age, histological subtype, tumor grade, tumor stage, ER-expression, year of diagnosis, neo-adjuvant treatment, adjuvant chemotherapy, and adjuvant endocrine therapy, an adjusted HR of 0.55 (95% CI 0.37-0.81, p=0.003) was observed for RFS for patients with an above-median level of CD8+ TILs.